COULD MULTI-STAKEHOLDER PARTNERSHIP IMPROVE PATIENT ACCESS TO BETTER HEALTHCARE IN LATIN AMERICA?

Diego Rosselli MD EdM MSc
Pontificia Universidad Javeriana, Bogota, Colombia

ISPOR COLOMBIA CHAPTER

DISCLAIMER: I have been a lecturer for Abbott, Abbvie, Acordes, Alexion, Amgen, Astellas, Astrazeneca, Baxter, Bayer Schering, Biocodex, Biopax, Biotecnica, BristolMyersSquibb, Boehringer-Ingelheim, EBiLilly, Genzyme, Grünenthal, GlaxoSmithKline, Janssen, Lafrancol, Linde, Merck, MSD, Mundipharma, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi-Aventis, Sanofi-Pasteur, Shire, Stendhal, Takeda, USB, Zambon
Where are the important healthcare access-related decisions made?

The correct answer is: All of the above
Is it appropriate (or convenient) to get all of them together?

What barriers do we have to overcome to interact with all the stakeholders?

#1 is lack of confidence
Strengthening patients and patient organizations is essential.
Our webpage

https://trc-val.dcri.duke.edu/conc/Pages/stakeholder-engagement.aspx

Is ISPOR responsible for improving access to healthcare?